Search

Displaying results 2311 - 2320 of 4359 in total
  1. Drug

    Colistin

    go.drugbank.com/drugs/DB00803
    ApprovedInvestigational

    It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes.

  2. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.

  3. Drug

    Zaleplon

    go.drugbank.com/drugs/DB00962
    ApprovedIllicit

    It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines.

  4. Drug

    Diosmetin

    go.drugbank.com/drugs/DB11259
    Approved

    It also acts as a weak TrkB receptor agonist [A27230].

  5. Drug

    Levomenol

    go.drugbank.com/drugs/DB13153
    Approved

    Bisabolol, or more formally α-(−)-bisabolol or also known as levomenol, (-)-alpha-Bisabolol is found in fats and oils. (-)-alpha-Bisabolol is isolated from essential oil of Matricaria chamomilla (German

  6. Drug

    Dichloralphenazone

    go.drugbank.com/drugs/DB01495
    ApprovedIllicit

    It is a US Schedule IV drug and its clinical use is limited.

  7. Drug

    Fidaxomicin

    go.drugbank.com/drugs/DB08874
    ApprovedInvestigational

    [A190501] Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug. … [A190492] The antibacterial activity of fidaxomicin is distinct from macrolides and rifamycins, as the bactericidal activity is time-dependent, and not concentration-dependent.

  8. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in c...

  9. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.

  10. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).